Forced Vital Capacity (FVC) decline, mortality and healthcare resource utilization in idiopathic pulmonary fibrosis

References

• Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–13.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet. 2017;389:1941–1952.
   PubMed Web of Science ®Google Scholar
• Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161:19.
   Google Scholar
• Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a fleischner society white paper. Lancet Respir Med. 2018;6:138–153.
   PubMed Web of Science ®Google Scholar
• Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44–e68.
   PubMed Web of Science ®Google Scholar
• Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192:e3–e19.
   PubMed Web of Science ®Google Scholar
• Sköld CM, Bendstrup E, Myllärniemi M, et al. Treatment of idiopathic pulmonary fibrosis: a position paper from a nordic expert group. J Intern Med. 2017;281:149–166.
   PubMed Web of Science ®Google Scholar
• Hodgson U. Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax. 2002;57:338–342.
   PubMed Web of Science ®Google Scholar
• Kaunisto J, Kelloniemi K, Sutinen E, et al. Re-evaluation of diagnostic parameters is crucial for obtaining accurate data on idiopathic pulmonary fibrosis. BMC Pulm Med. [Internet] 2015 [cited 2019 Jan 21]; 15. Available from: http://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-015-0074-3
   Web of Science ®Google Scholar
• Sgalla G, Biffi A, Richeldi L. Idiopathic pulmonary fibrosis: diagnosis, epidemiology and natural history: IPF: diagnosis, epidemiology, course. Respirology. 2016;21:427–437.
   PubMed Web of Science ®Google Scholar
• Kennedy-Martin T, Curtis S, Faries D, et al. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. [Internet] 2015 [cited 2019 Jan 15]; 16. Available from: http://trialsjournal.biomedcentral.com/articles/10.1186/s13063-015-1023-4
   Web of Science ®Google Scholar
• King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083–2092.
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2016;47:243–253.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Cottin V, Du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS® trials. Respir Med. 2016;113:74–79.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–2082.
   PubMed Web of Science ®Google Scholar
• Albera C, Costabel U, Fagan EA, et al. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J. 2016;48:843–851.
   PubMed Web of Science ®Google Scholar
• Kolb M, Richeldi L, Behr J, et al. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax. 2017;72:340–346.
   PubMed Web of Science ®Google Scholar
• 284 Nintedanib och pirfenidon [Internet]. kela.sv [ cited 2019 Jan 22]. Available from: https://www.kela.fi/web/sv/lakemedel284.
   Google Scholar
• Collard HR, Ward AJ, Lanes S, et al. Burden of illness in idiopathic pulmonary fibrosis. J Med Econ. 2012;15:829–835.
   PubMedGoogle Scholar
• Jo HE, Glaspole I, Moodley Y, et al. Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry. BMC Pulm Med. [Internet] 2018 [cited 2019 Jan 21]; 18. Available from: https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-018-0575-y
   Web of Science ®Google Scholar
• Song JW, Hong S-B, Lim C-M, et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011;37:356–363.
   PubMed Web of Science ®Google Scholar
• Tarride J-E, Hopkins RB, Burke N, et al. Clinical and economic burden of idiopathic pulmonary fibrosis in Quebec, Canada. Clin Outcomes Res. 2018;10:127–137.
   Web of Science ®Google Scholar
• Vaidya S, Hibbert CL, Kinter E, et al. Identification of key cost generating events for idiopathic pulmonary fibrosis: a systematic review. Lung. 2017;195:1–8.
   PubMed Web of Science ®Google Scholar
• Wu N, Yu YF, Chuang -C-C, et al. Healthcare resource utilization among patients diagnosed with idiopathic pulmonary fibrosis in the USA. J Med Econ. 2015;18:249–257.
   PubMed Web of Science ®Google Scholar
• Lamas DJ, Kawut SM, Bagiella E, et al. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am J Respir Crit Care Med. 2011;184:842–847.
   PubMed Web of Science ®Google Scholar
• Purokivi M, Hodgson U, Myllärniemi M, et al. Are physicians in primary health care able to recognize pulmonary fibrosis? Eur Clin Respir J. 2017;4:1290339.
   PubMed Web of Science ®Google Scholar
• Graney BA, Lee JS. Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives. Patient Relat Outcome Meas. 2018;9:321–328.
   Web of Science ®Google Scholar
• Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431–440.
   PubMed Web of Science ®Google Scholar
• Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA. 2013;309:2232.
   PubMed Web of Science ®Google Scholar
• Vancheri C, Failla M, Crimi N, et al. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J. 2010;35:496–504.
   PubMed Web of Science ®Google Scholar
• Raimundo K, Chang E, Broder MS, et al. Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study. BMC Pulm Med. [Internet] 2016 [cited 2019 Jan 21]; 16. Available from: http://www.biomedcentral.com/1471-2466/16/2
   Web of Science ®Google Scholar
• Teramachi R, Kondoh Y, Kataoka K, et al. Outcomes with newly proposed classification of acute respiratory deterioration in idiopathic pulmonary fibrosis. Respir Med. 2018;143:147–152.
   PubMed Web of Science ®Google Scholar
• Hutchinson J, Fogarty A, Hubbard R, et al. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J. 2015;46:795–806.
   PubMed Web of Science ®Google Scholar